Calquence shows long-term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma
ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of Calquence in mantle cell lymphomaLong-term follow-up results from the positive ACE-LY-004 Phase II trial showed patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up. The safety and tolerability profile remained consistent.[1 ]These results were presented at the 62nd American Society of Hematology (ASH) Annual Meeting and